Clinical Trials
103 trialsNCT02632708 2026-05-22
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Active not recruiting
NCT04195945 2026-05-14
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT03983824 2026-05-13
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03182244 2026-05-05
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT04293562 2026-05-05
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT03591510 2026-04-27
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
NCT03164057 2026-04-23
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT05955261 2026-04-23
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Suspended
NCT04797767 2026-04-17
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
Phase 1/2 Recruiting
NCT06660368 2026-04-01
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03150004 2026-03-30
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Phase 2 Terminated
NCT04375631 2026-03-05
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT01371981 2025-11-26
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06451861 2025-11-17
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT02521493 2025-08-01
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group
Phase 3 Active not recruiting
NCT00410423 2025-04-30
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Thomas Jefferson University
Phase 1/2 Completed
NCT03839446 2025-02-20
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
University of Pittsburgh
Phase 2 Completed
NCT03441048 2024-10-08
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 1 Completed
NCT02484391 2024-09-19
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT06007911 2024-08-13
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 1 Withdrawn
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04196010 2023-12-28
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
University of Washington
Phase 1 Terminated
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02583893 2023-10-10
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Thomas Jefferson University
Phase 2 Completed
NCT03531918 2023-08-30
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02728050 2023-07-05
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
Phase 1/2 Completed
NCT02299518 2023-06-15
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT00003407 2023-02-02
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Rush University Medical Center
Phase 2 Withdrawn
NCT01154439 2022-10-26
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 1 Completed
NCT01842672 2022-10-25
MITCL
New York Medical College
Phase 1/2 Completed
NCT02686593 2022-10-06
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
The University of Hong Kong
Phase 2 Completed
NCT03173612 2022-08-03
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT03563560 2022-04-12
AML
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT03012672 2022-03-08
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
University of Washington
Phase 2 Completed
NCT02756572 2021-11-08
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
Phase 2 Completed
NCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT02724163 2021-10-08
Myechild01
University of Birmingham
Phase 3 Recruiting
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT00372593 2021-03-24
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Completed
NCT01839240 2020-05-15
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
University of Chicago
Phase 1 Completed
NCT01830777 2020-04-14
Brentuximab Vedotin + Re-induction Chemotherapy for AML
Massachusetts General Hospital
Phase 1 Completed
NCT02573363 2020-04-08
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
Phase 1 Completed
NCT02921061 2020-03-17
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
Phase 1/2 Completed